Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;55(8):2352-6.
doi: 10.1007/s10620-010-1182-9. Epub 2010 Mar 19.

Is BRAF mutation associated with interval colorectal cancers?

Affiliations

Is BRAF mutation associated with interval colorectal cancers?

Aasma Shaukat et al. Dig Dis Sci. 2010 Aug.

Abstract

Introduction: Colon cancers diagnosed in the interval after a complete colonoscopy may occur due to limitations of colonoscopy or due to rapid tumor growth. The aim of this study was to compare the association of BRAF V600E mutation in interval versus non-interval colorectal cancers and to determine the relationship between BRAF mutation and 5-year survival.

Methods: We searched our institution's cancer registry for interval cancers, defined as colon cancers that developed within 5 years of a complete colonoscopy. These were frequency matched to patients with non-interval cancers. Archived cancer specimens were tested for BRAF V600E mutation and MSI.

Results: There were 63 interval and 131 non-interval cancers. BRAF mutation was present in 28% of interval cancers compared to 19% of non-interval cancers (P = 0.18). In a multivariable logistic regression model, proximal location (OR 1.85; 95% CI 1.01-3.8) and MSI (OR 2.7; 95% 1.1-6.8) were independently associated with interval cancers while BRAF mutation was not (OR 0.93; 95% CI 0.36-2.38). BRAF mutation portended a poor 5-year survival, particularly among microsatellite stable cancers.

Conclusions: BRAF mutation is not associated with interval cancers but is a marker of poor prognosis, particularly in microsatellite stable cancers.

PubMed Disclaimer

References

    1. Cancer Res. 2005 Jul 15;65(14):6063-9 - PubMed
    1. Gut. 2009 Jan;58(1):90-6 - PubMed
    1. Virchows Arch. 2007 May;450(5):529-37 - PubMed
    1. Cancer. 2009 Feb 15;115(4):760-9 - PubMed
    1. Gastroenterology. 2002 May;122(5):1376-87 - PubMed

Publication types

Substances